IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Novo Nordisk shares plunge as obesity drug trails Eli Lilly in head to head trial

Novo Nordisk shares fell Monday after its drug CagriSema trailed Eli Lilly's tirzepatide in a trial. The drug achieved slightly less weight loss than its rival.

Novo Nordisk announced on Monday that its experimental obesity treatment CagriSema failed to meet the primary endpoint in a clinical trial designed to show the drug was non-inferior to Eli Lilly’s tirzepatide. Following the public announcement, shares in the company based in Denmark DKDK fell by approximately 8% by 09:46 GMT on February 23, 2026.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on December 3, 2025. REUTERS/Tom Little//File Photo
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on December 3, 2025. REUTERS/Tom Little//File Photo
IUX24

IUX24 AI-powered financial news and market intelligence. Think and act like smart money.

IFZA Properties, Dubai Silicon Oasis, DSO-IFZA, Dubai, United Arab Emirates

Copyright IUX24 MEDIA - FZCO. All rights reserved.

Powered by AI • Made with precision

IUX24 is an information and analytics platform providing news, market data, analytical tools, and AI-powered features for informational and educational purposes. The Services and information provided do not constitute investment advice, trading signals, or brokerage services. Investing involves risk, and Users should carefully evaluate information before making investment decisions.